The U.K. drug regulator on Wednesday approved Amgen’s (NASDAQ:AMGN) intravenous medication teprotumumab (Tepezza) as the ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) yesterday approved Tepezza (teprotumumab (Tepezza). This ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Amgen’s Tepezza ...

It’s been 19 months since Amgen completed its $27.8 billion acquisition of Horizon Therapeutics, and the California company ...

In the weeks to come, the European Commission will issue a decision on the first severe thyroid eye disease treatment.

The European Medicines Agency (EMA) has recommended marketing authorization for Tepezza (teprotumumab) for adults with ...

As with all products, the MHRA will keep its safety under close review. The Medicines and Healthcare products Regulatory ...

Thyroid eye disease (TED) therapy Tepezza – the biggest asset in Amgen's $26 billion takeover of Horizon last year – could soon face competition from a drug in the same class from Viridian ...

EMA recommends marketing approval for Amgen Europe’s Tepezza to treat adults with moderate to severe thyroid eye disease: Amsterdam, The Netherlands Monday, April 28, 2025, 11:0 ...

Amgen on Thursday said its first-quarter profit rose 24%, handily exceeding Wall Street expectations, as product sales ...

Tepezza remains the only therapy approved by the U.S. Food and Drug Administration (FDA) for thyroid eye disease.The biotech is aiming for regulatory approvals for this medicine in other countries ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) yesterday approved Tepezza (teprotumumab (Tepezza). This ...